VISTA Monoclonal Antibody (MH5A), Functional Grade, eBioscience™, Invitrogen™

Description

Description: The monoclonal antibody MH5A reacts with a homolog of PD-1 (PD-1H) also known as VISTA. PD-1H is a 309 aa type I transmembrane protein that belongs to the CD28 superfamily. This cell surface receptor is expressed on nearly all hematopoietic cells except B cells. VISTA negatively regulates T cell responses by suppressing early TCR activation, inhibiting cell proliferation, and suppressing TH1 cytokine production. The MH5A antibody has been reported to inhibit T cell infiltration in graft-versus-host disease mouse models. Applications Reported: This MH5A antibody has been reported for use in flow cytometric analysis. Applications Tested: This MH5A antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 μm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.

VISTA (V-domain Ig containing suppressor of T-cell activation), also known as B7-H5 or PD-1H, is a product of the VSIR gene. Although VISTA bears sequence homology to PD-L1 it has a different expression pattern. In both mouse and humans, VISTA is expressed predominantly on hematopoietic cells with the highest densities on myeloid cells, and lower levels on T cells. It is usually absent on B cells. VISTA expressed by antigen presenting cells has been shown to directly suppress proliferation and cytokine production of CD4 and CD8 T cells, making it a target for cancer immunotherapy. The reported ligands of VISTA include CD28H, VSIG-3 and VSIG-8.